2024: First mRNA RSV Vaccine

On This Day in Health: May 31, 2024

On May 31, 2024, the U.S. Food and Drug Administration approved mResvia, Moderna's mRNA vaccine against respiratory syncytial virus, or RSV. The original indication was prevention of lower respiratory tract disease caused by RSV in adults sixty years of age and older. It was the first approved mRNA RSV vaccine and the first approved mRNA vaccine for a disease other than COVID-19. It was not the first RSV vaccine: other products had received approval in 2023. The anniversary marks a new use of a vaccine platform within an already developing field of prevention for older adults.

RSV is often associated with childhood illness, but it can also cause serious respiratory disease in older people. Age, underlying heart or lung disease and weakened immune defenses can increase the consequences of an infection. mResvia uses messenger RNA carried in lipid nanoparticles to provide instructions for a version of the virus's fusion protein in its prefusion form. This gives the immune system a target to recognize. The vaccine does not contain a complete live RSV virus. Its design connects research on the shape of a viral protein with a delivery approach that had already reached large-scale clinical use during the COVID-19 pandemic.

The approval drew on the ConquerRSV clinical program, which compared the vaccine with placebo in older adults. Investigators followed cases of RSV-associated lower respiratory tract disease, providing evidence about a defined clinical outcome rather than assuming that an immune response alone established protection. The review also considered safety findings, including commonly reported reactions such as injection-site pain and fatigue. No vaccine guarantees that every recipient will avoid illness. The age group and disease outcome in the original approval are therefore important when explaining the evidence. Approval also remained distinct from the public-health recommendations that guide who should be offered vaccination and when it should be given.

The significance of May 31 reaches beyond the addition of another product. It showed that the mRNA approach could move from pandemic use into prevention of another respiratory infection with a substantial effect on older adults. At the same time, the decision belonged to a broader story that included earlier RSV vaccines, years of protein research and the volunteers who joined the trials. Remembering the date means keeping those contributions connected. The milestone expanded prevention choices for a defined population while leaving questions of access, suitability and follow-up to ongoing clinical and public-health work. It was a step in reducing the burden of RSV disease, rather than a declaration that respiratory infections had ceased to be a concern.